CTLA4 and hepatocellular carcinoma: The advent of immunotherapy with immune checkpoint inhibitors (ICIs)-antibodies that block the PD-1/PD-L1 pathway or CTLA-4 revolutionized systemic HCC therapy, and their use in combination with anti-VEGF antibodies has significantly improved the outcomes of patients with advanced HCC [89].